证券代码：603235 证券简称：天新药业 公告编号：2026-002 江西天新药业股份有限公司关于2026年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 是否需要提交股东会审议：否 （一）日常关联交易履行的审议程序 1、董事会审议情况 公司于2026年1月26日召开第三届董事会第十三次会议，审议通过了《关于2026年度日常关联交易预计 的议案》，董事会在对该关联交易议案进行表决时，关联董事许江南、许晶、王光天对该议案回避表 决，其他参与表决的非关联董事以6票同意、0票反对、0票弃权的表决结果审议通过了该项议案。 鉴于公司2026年度日常关联交易的预计额度在董事会决策权限内，该议案无需提交股东会审议。 2、独立董事专门会议审议情况 在董事会审议前，公司独立董事于2026年1月22日召开的第三届董事会第三次独立董事专门会议对上述 议案进行了审核，以3票同意、0票反对、0票弃权的表决结果审议通过了《关于2026年度日常关联交易 预计的议案》，全体独立董事发表意见如下：公司本次对202 ...

江西天新药业股份有限公司 关于 2026 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、日常关联交易的基本情况 证券代码：603235 证券简称：天新药业 公告编号：2026-002 （一）日常关联交易履行的审议程序 1、董事会审议情况 公司于 2026 年 1 月 26 日召开第三届董事会第十三次会议，审议通过了 《关于 2026 年度日常关联交易预计的议案》，董事会在对该关联交易议案进行 表决时，关联董事许江南、许晶、王光天对该议案回避表决，其他参与表决的 非关联董事以 6 票同意、0 票反对、0 票弃权的表决结果审议通过了该项议案。 鉴于公司 2026 年度日常关联交易的预计额度在董事会决策权限内，该议案 无需提交股东会审议。 2、独立董事专门会议审议情况 在董事会审议前，公司独立董事于 2026 年 1 月 22 日召开的第三届董事会 第三次独立董事专门会议对上述议案进行了审核，以 3 票同意、0 票反对、0 票 是否需要提交股东会审议：否 日常关联交易对上市公司的影响 ...

Group 1 - The sixth Asian Beach Games will hold a press conference on January 12, 2023, to discuss the preparation status [2] - Shanghai Disneyland will implement a tiered refund policy starting January 12, 2026, allowing full refunds up to 7 days before the visit [3] - A total of 9 companies will have their restricted shares unlocked on January 12, with a total unlock volume of 742 million shares, valued at 17.761 billion [4] Group 2 - One company has disclosed its stock repurchase progress, with BOE Technology Group completing a repurchase amounting to 1.5 billion [5] - Seven A-shares will undergo equity registration on January 12, with significant dividends announced, including Hai Kan Co. distributing 5.20 yuan per 10 shares [6] - Economic data such as the Eurozone Sentix Investor Confidence Index and India's CPI for December 2025 will be released [7]

Group 1 - On January 12, a total of 4 listed companies had their restricted shares unlocked, with a total market value of approximately 6.055 billion yuan [1] - The specific details of the restricted share unlocks are as follows: [1] - Zhongbai Group (Stock Code: 000759) had 7.3776 million shares unlocked under equity incentive restrictions [1] - Xianghe Industrial (Stock Code: 603500) had 554,000 shares unlocked under equity incentive restrictions [1] - Tianxin Pharmaceutical (Stock Code: 603235) had 263 million shares unlocked with an extended lock-up period [1] - Fulei New Materials (Stock Code: 605488) had 40,000 shares unlocked under equity incentive restrictions [1]

Market News - China will release December import and export data on January 14, with exports expected to grow by 3.0% year-on-year, down from 5.9% in November, while imports are anticipated to decline by 2.9% [3] - The trade balance for December 2025 will also be published on January 14, with total goods trade from January to November 2025 reaching 41.21 trillion yuan, a year-on-year increase of 3.6% [3] Commodity Futures - The Shanghai Futures Exchange will adjust the price limit for platinum and palladium futures contracts to 16% starting from January 13, 2026, with the trading margin standard set at 18% [4] Energy Outlook - The U.S. Energy Information Administration (EIA) will release its Short-Term Energy Outlook report on January 13, maintaining the WTI crude oil price forecast for 2025 at slightly below $69 per barrel [5] U.S. Economic Data - The U.S. will release December CPI data on January 13, with core CPI expected to rebound significantly, predicted at 0.36% by Morgan Stanley and 0.38% by Bloomberg, both higher than the average of 0.08% in October and November [6] - Key economic indicators including October and November PPI and November retail sales will also be released, with expectations of moderate PPI growth and a 0.7% rebound in retail sales for November [6] Federal Reserve - The Federal Reserve will publish its latest Beige Book on January 14, indicating that government shutdowns and AI applications have weakened the job market, while rising tariffs and healthcare costs have increased business expenses [7] Earnings Season - The earnings season for Q4 2025 will commence this week, with major banks including JPMorgan, Citigroup, and Goldman Sachs set to report [8] Sector Events - The second China eVTOL Innovation Development Conference is scheduled for January 15-16, 2026, in Shanghai, focusing on the new commercial era of eVTOL [10] - The fourth Data Center Liquid Cooling & AI Chip Thermal Management Supply Chain Conference will be held on January 14-15, 2026, in Shenzhen [10] - China's first comprehensive law in the nuclear energy sector, the Atomic Energy Law, will take effect on January 15, 2026 [11] Individual Company News - Hangyu Technology announced on January 11 that it has repurchased 752,800 shares, with plans to sell them within six months [13] - Huadong Medicine's subsidiary has developed a breakthrough treatment for severe hypertriglyceridemia, which has been included in the list of breakthrough therapies by the National Medical Products Administration [13] - Jingfeng Mingyuan plans to acquire 100% of Sichuan Yichong Technology Co., with a key review meeting scheduled for January 16, 2026 [13] - TSMC has commenced research on its next-generation 1.4nm process, with risk trial production expected to start in 2027 [13] Lock-up Expiration - From January 12 to January 16, 2026, 23 companies will have lock-up shares released, totaling 2.434 billion shares with a market value of approximately 48.56 billion yuan [16] - The highest market value of lock-up shares released on January 12 is from Tianxin Pharmaceutical at 7.84 billion yuan [17] New Stock Calendar - Two new stocks are set to be issued this week, with a total issuance of approximately 34 million shares and expected fundraising of 1.909 billion yuan [19] Market Outlook - The current market enthusiasm is driven by concentrated inflows from previously cautious funds, with expectations for continued momentum in thematic and small-cap stocks until after the Two Sessions [22] - Guojin Securities suggests that the spring market is likely to perform well, with a focus on AI investments and the recovery of domestic manufacturing [23] - Everbright Securities anticipates sustained market heat but warns of potential cooling as the Lunar New Year approaches, recommending attention to sectors like electronics and power equipment [24]

Group 1 - The core point of the news is that Jiaoyun Co., Ltd. is planning a significant asset swap involving its passenger car sales and automotive after-service segments with assets related to the cultural and entertainment industry held by its controlling shareholder, Jiushi Group, and its affiliates [1] - The transaction is expected to constitute a major asset restructuring, with the price difference between the assets to be settled in cash [1] - The transaction price has not yet been determined [1] Group 2 - On January 9, Jiaoyun Co., Ltd. closed at the daily limit, with a total market value of 6.983 billion yuan [2] - Next week, a total of 23 stocks will have their shares unlocked, amounting to 2.434 billion shares, with a total unlock market value of 48.556 billion yuan based on the latest closing prices [5] - Among the stocks with significant unlock pressure, Zhongke Lanyun is expected to have the highest unlock market value at 11.087 billion yuan, followed by Tianxin Pharmaceutical at 7.841 billion yuan [6][7]

证券代码：603235 证券简称：天新药业 公告编号：2026-001 江西天新药业股份有限公司首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 二、本次限售股形成后至今公司股本数量变化情况 本次限售股形成后至今，公司未发生配股、公积金转增股本等事项，股本数量未发生变化。 三、本次限售股上市流通的有关承诺 江西天新药业股份有限公司（以下简称"公司"）经中国证券监督管理委员会于2022年6月13日出具的 《关于核准江西天新药业股份有限公司首次公开发行股票的批复》（证监许可〔2022〕1220号）的核 准，公司首次公开发行人民币普通股（A股）4,378万股，每股面值1.00元，每股发行价格36.88元，公司 股票于2022年7月12日起在上海证券交易所上市交易。首次公开发行后，公司总股本为437,780,000股， 其中有限售条件的流通股为394,000,000股，占公司总股本的90%。 本次上市流通的限售股为公司首次公开发行限售股，涉及股东为许江南先生、许晶女士、天台县厚鼎投 ...

证券代码：603235 证券简称：天新药业 公告编号：2026-001 江西天新药业股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为 首发 股份；股票认购方式为 网下 ，上市股数为 290,714,800股。 三、本次限售股上市流通的有关承诺 根据《江西天新药业股份有限公司首次公开发行股票招股说明书》，本次解 除股份限售的股东就股份锁定事宜承诺如下： （一）公司控股股东、实际控制人许江南及实际控制人许晶承诺： 本次股票上市流通总数为290,714,800股。 本次股票上市流通日期为2026 年 1 月 12 日。 一、本次限售股上市类型 江西天新药业股份有限公司（以下简称"公司"）经中国证券监督管理委员 会于 2022 年 6 月 13 日出具的《关于核准江西天新药业股份有限公司首次公开发 行股票的批复》（证监许可〔2022〕1220 号）的核准，公司首次公开发行人民币 普通股（A 股）4,378 万股，每股面值 1.00 元，每股发行价格 ...

中信证券股份有限公司 关于江西天新药业股份有限公司 首次公开发行部分限售股上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江西天 新药业股份有限公司（以下简称"天新药业"或"公司"）首次公开发行股票并 上市的保荐人，根据《首次公开发行股票注册管理办法》《证券发行上市保荐业 务管理办法》《上海证券交易所股票上市规则（2025 年 4 月修订）》《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》等有关规定，对天新药业首次 公开发行部分限售股上市流通的事项进行了专项核查，核查情况如下： 一、本次限售股上市类型 天新药业经中国证券监督管理委员会于 2022 年 6 月 13 日出具的《关于核准 江西天新药业股份有限公司首次公开发行股票的批复》（证监许可〔2022〕1220 号）的核准，公司首次公开发行人民币普通股（A 股）4,378 万股，每股面值 1.00 元，每股发行价格 36.88 元，公司股票于 2022 年 7 月 12 日起在上海证券交易所 上市交易。首次公开发行后，公司总股本为 437,780,000 股，其中有限售条件的 流通股为 394,000,000 股 ...

南财智讯1月5日电，天新药业公告，本次上市流通的限售股总数为29071.48万股，占公司总股本的 66.41%。本次上市流通日期为2026年1月12日。本次限售股为公司首次公开发行部分限售股，涉及股东 包括许江南、许晶、天台县厚鼎投资管理合伙企业（有限合伙）、天台县厚盛投资管理合伙企业（有限 合伙）及天台县厚泰投资管理合伙企业（有限合伙）。上述股东持有的限售股锁定期已届满，将自2026 年1月12日起上市流通。本次限售股上市流通后，公司有限售条件的流通股将减少29071.48万股，无限 售条件的流通股相应增加。 ...